| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Siegel Jonathan B. | Director | C/O JAGUAR HEALTH, INC., 200 PINE STREET, SUITE 400, SAN FRANCISCO | /s/ Jonathan B. Siegel | 26 Jun 2025 | 0001588209 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | JAGX | Convertible Promissory Note | Disposed to Issuer | $450,000,000 | -9,000 | -100% | $50000.00 | 0 | 24 Jun 2025 | Common Stock | 9,000 | $5.56 | See footnote | F1, F3 |
| transaction | JAGX | Convertible Promissory Note | Award | $473,100,000 | +9,462 | $50000.00 | 9,462 | 24 Jun 2025 | Common Stock | 9,462 | $5.56 | See footnote | F1, F3 | |
| transaction | JAGX | Warrant to Purchase Common Stock | Award | +18,262 | 9,000 | 24 Jun 2025 | Common Stock | 18,262 | $2.70 | See footnote | F2, F3 |
| Id | Content |
|---|---|
| F1 | The reporting person disposed of a 6% convertible promissory note maturing on 6/30/2025 (the "Original Note") that was originally issued to pursuant to a securities purchase agreement between Jaguar Health, Inc. (the "Company") and the reporting person dated March 26, 2025 in exchange for a new 6% convertible promissory note that matures on 1/30/2026 (the "New Note") in an issuer exchange offer. The New Note is convertible, at the reporting person's option, in part or in full, into an aggregate of 9,462 shares of the Company's voting common stock, par value $0.0001 per share (the "Common Stock"), at a conversion price of $5.555 per share. |
| F2 | As an inducement to enter into the issuer exchange offer, the reporting person received a warrant (the "Warrant") to purchase up to 18,262 shares of Common Stock with an exercise price of $2.70 per share. The Warrant is exercisable immediately upon receipt of stockholder approval and will expire on the earlier of (i) 18 months from the date of issuance, (ii) the consummation of a fundamental transaction and (iii) the consummation of a liquidation event. |
| F3 | Securities held directly by JBS Healthcare Ventures LLC. Mr. Siegel, by virtue of his position as the sole member of JBS Healthcare Ventures LLC, may be deemed to beneficially own the securities held by JBS Healthcare Ventures LLC for purposes of Section 16 |